

1. A scavenger compound of the general formula I

$$\begin{array}{c|c}
 & R_4 \\
 & R_3 - R_2 - Z
\end{array}$$

in which

X denotes a 4 - 10 memebered ring;

R₁ and R₂ are independently alkyl or alkylene;

R₃ denotes H, carboxy, amido, alkanol, amino, carboxyalcohol, alkanediol, amine alcohol, amine diol, thio or amine carbonyl;

$$PO_3H_2$$

$$R_4 \text{ denotes H or-n} \longrightarrow D \longrightarrow n' \longrightarrow OH;$$

$$PO_3H_2$$

n and n' are, independently, an integer from 0 to 8;

D denotes CH2 or NH;

Z denotes a 4 - 10 memebered di sulfide ring or R₄.

- 2. A compound according to claim 1 wherein X denotes a 4, 5 or 6 membered ring and Z denotes a 4, 5 or 6 membered di sulfide ring or R4.
- 3. A compound according to claim 1 wherein R_1 and R_2 are C_{1-10} alkyls or alkylenes.
- 4. A compound according to claim 1 wherein R₁ or R₂ or both are substituted.
- 5. A compound according to claim 4 wherein R₁ or R₂ or both are substituted by substituents selected from the group consisting of halogen atoms, halomethyl groups oxo, hydroxy, carboxy, caiboxyalkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl and aryloyloxy, amino, alkylamino, dialkylamino, cyano, azido and nitro,

WO 00/3106

thiol. alkyltmoi, sulphonyl, sulphoxide, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, inlidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl. isoquinolyl. naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl, carbolinyl, substituted or unsubstituted alkyl groups, and substituted or unsubstituted aryl groups.

A method for the preparation of a compound according to claim 1 comprising the step of performing reduction or oxidation of a compound of the general formula II

and a compound of the general formula III

in the presence of a reducing or oxidizing agent and a solvent.

- 7. A method for treating a patient afflicted with conditions associated with oxidative stress or free radical injury comprising the step of administering to the patient an effective amount of the compound according to claim 1.
- A method according to claim 7 wherein with conditions associated with oxidative stress or free radical injury are selected from aging-mediated changes, pulmonary and ocular hypertension, asthma and other related respiratory diseases, trauma, neurotoxicity, neurological and neurodegenerative disorders, AIDS-related disorders, disorders of gastric acid and other secretary and peristaltic functions of the alimentary system, inflammatory bowel diseases (Crohn's disease and ulcerative

wo 00/31060 pct/1L99/00638 colitis), drug a sease-induced neuropathy and nephropathy, pathological and premature uterine contractions, chemotactic, phagocytic and other cellular defense impairment in immunological disorders, aggregation disorders, pregnancy-induced hypertension, cerebrovascular diseases, and male impotence.

- 9. A method according to claim 7 wherein the compound is administered orally.
- 10. A pharmaceutical composition comprising the compound according to claim 1 together with a pharmaceutically acceptable excipient.
- Use of the compound according to claim 1 in the preparation of a medicament for the treatment of conditions associated with oxidative stress or free radical injury.
- 2. Use according to claim 11 wherein conditions associated with oxidative stress or free radical injury are selected from aging-mediated changes, pulmonary and ocular hypertension, asthma and other related respiratory diseases, trauma, neurotoxicity, neurological and neurodegenerative disorders, AIDS-related disorders, disorders of gastric acid and other secretary and peristaltic functions of the alimentary system, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), drug and disease-induced neuropathy and nephropathy, pathological and premature uterine contractions, chemotactic, phagocytic and other cellular defense impairment in immunological disorders, aggregation disorders, pregnancy-induced hypertension, cerebrovascular diseases, and male impotence.